The estimated Net Worth of Ravi Sachdev is at least $1.11 Million dollars as of 11 May 2022. Mr. Sachdev owns over 7,718 units of Covetrus stock worth over $799,614 and over the last 16 years he sold CVET stock worth over $0. In addition, he makes $312,500 as Independent Director at Covetrus.
Ravi has made over 2 trades of the Covetrus stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 7,718 units of CVET stock worth $162,001 on 11 May 2022.
The largest trade he's ever made was exercising 24,089 units of Covetrus stock on 13 May 2021 worth over $505,628. On average, Ravi trades about 1,515 units every 17 days since 2008. As of 11 May 2022 he still owns at least 38,095 units of Covetrus stock.
You can see the complete history of Mr. Sachdev stock trades at the bottom of the page.
Ravi Sachdev is Independent Director of the Company. Prior to such appointment, Mr. Sachdev served from July 2015 as a member of the Vets First Choice Board. As a Partner of the private equity firm Clayton, Dubilier & Rice (“CD&R”) since June 2015, Mr. Sachdev focuses on the healthcare sector. From November 2010 to May 2015, Mr. Sachdev was a Managing Director and Co-Head of Healthcare Services at J.P. Morgan Chase & Co., a financial services company. Prior to November 2010, Mr. Sachdev held the positions of Managing Director at Deutsche Bank Securities, Inc., an investment banking firm, from January 2009 until November 2010 and Director at Deutsche Bank AG from January 2007 until January 2009. Prior to joining Deutsche Bank AG in 2006 as a Vice President, Mr. Sachdev served as a Vice President at Peter J. Solomon Company, an investment banking firm, specializing in mergers and acquisitions in the healthcare sector, from 1998 to 2006. Mr. Sachdev serves on the Board of Directors of Healogics, Inc. and Agilon Health, Inc. He also serves on the Board of Directors of naviHealth, Inc., a private technology enabled health services company. Mr. Sachdev holds a B.A. from the University of Michigan. Mr. Sachdev possesses knowledge of finance and the financial analytics used to measure business performance. Mr. Sachdev’s 20 years of professional experience in investment banking and private equity, thorough understanding of the financial issues affecting public companies, insights into business valuation and practical orientation with respect to acquisitions and integrations led to the conclusion that he should serve as a member of the Covetrus Board.
As the Independent Director of Covetrus, the total compensation of Ravi Sachdev at Covetrus is $312,500. There are 9 executives at Covetrus getting paid more, with Benjamin Wolin having the highest compensation of $4,065,210.
Ravi Sachdev is 43, he's been the Independent Director of Covetrus since 2019. There are 26 older and no younger executives at Covetrus. The oldest executive at Covetrus, Inc. is Philip Laskawy, 78, who is the Independent Chairman of the Board.
Ravi's mailing address filed with the SEC is C/O STEVEN MADDEN, LTD., 52-16 BARNETT AVENUE, LONG ISLAND CITY, NY, 11104.
Over the last 5 years, insiders at Covetrus have traded over $10,243,394 worth of Covetrus stock and bought 11,744 units worth $216,180 . The most active insiders traders include Steven Paladino, Benjamin Wolin, and Philip A Laskawy. On average, Covetrus executives and independent directors trade stock every 10 days with the average trade being worth of $268,798. The most recent stock trade was executed by Rebecca Ann Kidd on 1 October 2022, trading 1,232 units of CVET stock currently worth $25,860.
Covetrus, Inc., together with its subsidiaries, operates as an animal-health technology and services company. It engages in the sale of animal-health consumable products, including proprietary and Covetrus branded products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, parasiticides, and vitamins and supplements to wholesale and retail customers. The company also offers value-added solutions that include, inventory management and e-commerce, as well as continuing education services for practitioners. In addition, it provides practice management software systems for veterinary practitioners and animal-health clinics, client communication services, reminders, data backup services, and hardware sales and support services. Further, the company engages in the distribution of finished goods pharmacy and specialty pharmaceutical compounding products, as well as shipping, manufacturer incentives, service fees, and data integration and support services. It serves animal-health and veterinary practices, and clinics in the companion-animal and equine markets primarily in North America, Europe, and the Asia Pacific. The company was formerly known as HS Spinco, Inc. Covetrus, Inc. was incorporated in 2018 and is headquartered in Portland, Maine.
Covetrus executives and other stock owners filed with the SEC include: